文献速递流行病学与生物统计真实世界研究与卫生经济

慢性肾衰竭的透析治疗:综述

Dialysis for Chronic Kidney Failure: A Review.
PubMed 文献 · JAMA · 2024-01-01

综述指出无推荐的eGFR起始透析阈值,应基于症状、实验室趋势、患者偏好及费用与可及性进行共享决策;血透与腹透5年死亡率观察性数据未见差异。

要点

  • 开始维持性透析后5年生存率约40%。
  • 无推荐的eGFR阈值用于启动透析,应共享决策确定时机。
  • 观察性数据显示血透与腹透5年死亡率无差异。

核心结论

  • 2021年美国超过54万患者因慢性肾衰竭接受维持性血透或腹透。
  • 开始维持性透析后5年生存率约40%,血透与腹透死亡率相似。
  • 透析启动时机与模式受患者症状、实验室趋势、患者偏好及治疗费用与可及性影响,应包含共享决策。

研究设计与样本

  • 综述,总结维持性血液透析或腹膜透析治疗慢性肾衰竭的观察与证据。

主要发现

  • 随机临床试验报告较高eGFR(10-14 mL/min/1.73 m2)起始透析相较较低eGFR(5-7 mL/min/1.73 m2)无死亡率获益。
  • 观察性数据提示血透与腹透5年死亡率无差异。
  • 美国血透导管相关血流感染发生率为每1000导管日1.1至5.5次,约50%患者在置管后6个月内发生。
  • 腹膜炎发生率为每患者年0.26次,约30%个体在腹膜透析治疗第一年内发生。

关键数值与推荐

  • 无推荐的eGFR阈值用于起始透析。
  • 持续尿毒症体征和症状(如恶心、乏力)及容量超负荷(如呼吸困难、外周水肿)、eGFR恶化、代谢性酸中毒和高钾血症可提示治疗启动时机。
  • 随机临床试验:较高eGFR(10-14 mL/min/1.73 m2)起始透析相较较低eGFR(5-7 mL/min/1.73 m2)无死亡率获益。
  • 观察性数据:血透与腹透5年死亡率无差异。

临床怎么用

  • 患者-临床医生共享决策应帮助确定何时起始透析。
  • 透析启动时机与模式决策应纳入共享决策,考虑患者症状、实验室趋势、患者偏好及治疗费用与可及性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: More than 3.5 million people worldwide and 540 000 individuals in the US receive maintenance hemodialysis or peritoneal dialysis for the treatment of chronic kidney failure. The 5-year survival rate is approximately 40% after initiation of maintenance dialysis. OBSERVATIONS: Hemodialysis and peritoneal dialysis remove metabolic waste and excess body water and rebalance electrolytes to sustain life. There is no recommended estimated glomerular filtration rate (eGFR) threshold for initiating dialysis, and patient-clinician shared decision-making should help determine when to initiate dialysis. Persistent signs and symptoms of uremia (eg, nausea, fatigue) and volume overload (eg, dyspnea, peripheral edema), worsening eGFR, metabolic acidosis, and hyperkalemia inform the timing of therapy initiation. A randomized clinical trial reported no mortality benefit to starting dialysis at higher eGFR (10-14 mL/min/1.73 m2) vs lower eGFR (5-7 mL/min/1.73 m2) levels. Observational data suggested no differences in 5-year mortality with use of hemodialysis vs peritoneal dialysis. Cardiovascular (eg, arrhythmias, cardiac arrest) and infection-related complications of maintenance dialysis are common. In the US, hemodialysis catheter-related bloodstream infections occur at a rate of 1.1 to 5.5 episodes per 1000 catheter-days and affect approximately 50% of patients within 6 months of catheter placement. Peritonitis occurs at a rate of 0.26 episodes per patient-year and affects about 30% of individuals in the first year of peritoneal dialysis therapy. Chronic kidney failure-related systemic complications, such as anemia, hyperphosphatemia, hypocalcemia, and hypertension, often require pharmacologic treatment. Hypotension during dialysis, refractory symptoms (eg, muscle cramps, itching), and malfunction of dialysis access can interfere with delivery of dialysis. CONCLUSIONS AND RELEVANCE: In 2021, more than 540 000 patients in the US received maintenance hemodialysis or peritoneal dialysis for treatment of chronic kidney failure. Five-year survival rate after initiation of maintenance dialysis is approximately 40%, and the mortality rate is similar with hemodialysis and peritoneal dialysis. Decisions about dialysis initiation timing and modality are influenced by patient symptoms, laboratory trajectories, patient preferences, and therapy cost and availability and should include shared decision-making.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Flythe JE, Watnick S. Dialysis for Chronic Kidney Failure: A Review. JAMA. 2024. PMID: 39356511. doi:10.1001/jama.2024.16338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。